

Sheet 1/34





FIG. 1A

Sheet 2/34

**FIG. 1B**




FIG. 2A

Sheet 4/34




FIG. 2B

Sheet 5/34




FIG. 3A

Sheet 6/34




FIG. 3B

Sheet 7/34






FIG. 3C


Sheet 8/34

AD vs NAND**FIG. 4A**

Sheet 9/34

**FIG. 4B**

Sheet 10/34

**FIG. 4C**

Sheet 11/34


AD vs All controls**FIG. 4D**

Table 1: Estimation of sensitivity, specificity, and predictive value for Aβ-PCMA in CSF¹

GROUPS	SENSITIVITY ²	SENSITIVITY ²	POSITIVE PREDICTIVE VALUE ²	NEGATIVE PREDICTIVE VALUE ²
AD vs NAND	100.0%	94.6%	96.2%	100.0%
AD vs NND	90.0%	84.2%	88.2%	86.5%
AD vs controls ³	90.0%	92.0%	88.2%	93.2%

1. For estimation of sensitivity, specificity and predictive value the results of the lag phase as shown in FIG. 9B were used. Cutoffs were estimated by Receiver Operating Characteristics (ROC) curve analysis using the MedCalc software.
2. Sensitivity was estimated by the formula: $\frac{\text{True positives}}{\text{True positives} + \text{False negatives}} \times 100$; specificity was estimated by the formula: $\frac{\text{True negatives}}{\text{False positives} + \text{True negatives}} \times 100$; positive predictive value was estimated by the formula: $\frac{\text{True positives}}{\text{True positives} + \text{False positives}} \times 100$; negative predictive value was estimated by the formula: $\frac{\text{True negatives}}{\text{True negatives} + \text{False negatives}} \times 100$
3. Controls refers to the samples from NND plus NAND.

FIG. 5

Sheet 13/34




FIG. 6

Sheet 14/34




FIG. 7A





FIG. 7B



Strategy 1: Using antibody-coated plates




FIG. 8A

Strategy 2: Immuno-precipitation and concentration by antibody-coated beads




FIG. 8B

Table 2



Antibody	Epitope	Commercial source	Aβ oligomer capturing capacity
82E1	1-5	IBL America	+++
4G8	18-22	Covance	+
6E10	3-8	Covance	++
X-40/42	C-terminal	Mybiosource	-
16 ADV Mouse IgG1	Conformational	Acumen	++
A11	Conformational	Invitrogen	-

+++

Best

++

very good

+

good

-

no result

FIG. 9

Sheet 20/34




FIG. 10

Sheet 21/34




FIG. 11




FIG. 12

Sheet 23/34




FIG. 13A




FIG. 13B

Sheet 25/34




FIG. 14

Sheet 26/34

Table 3

Antibodies (Company)	Epitope	Alpha-Synuclein oligomer capturing capacity
Alpha/beta-Synuclein Antibody N-19 (Santa Cruz Biotechnology)	N-terminal	+++
Alpha-Synuclein Antibody C-20-R (Santa Cruz Biotechnology)	C-terminal	+++
Alpha-Synuclein Antibody 211 (Santa Cruz Biotechnology)	Amino acids 121-125	++
Alpha-synuclein Antibody Syn-204 (Santa Cruz Biotechnology)	Fragment 1-130	+
16 ADV Mouse IgG1 (Acumen)	Conformational	-

+++***Best*****++*****very good*****+*****good*****-*****no result*****FIG. 15**

Using antibody-coated beads






FIG. 16A


Sheet 28/34

Detection of α -Synuclein oligomers spiked in human blood plasma**FIG. 16B**


Sheet 29/34

**FIG. 17A**

Sheet 30/34

**FIG. 17B**

Sheet 31/34

**FIG. 17C**

Sheet 32/34

Healthy Control




FIG. 18A

Sheet 33/34

Parkinson's disease




FIG. 18B

Sheet 34/34

Multiple System Atrophy




FIG. 18C